Sanofi’s (SNY) “Buy” Rating Reaffirmed at Leerink Swann
Sanofi (NYSE:SNY)‘s stock had its “buy” rating reissued by stock analysts at Leerink Swann in a research note issued on Sunday.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. TheStreet lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, August 22nd. Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a research note on Thursday, September 8th. Piper Jaffray Cos. started coverage on Sanofi in a research note on Friday, September 23rd. They issued a “neutral” rating for the company. Finally, BNP Paribas raised Sanofi from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 13th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $60.50.
Shares of Sanofi (NYSE:SNY) opened at 38.53 on Friday. The stock has a 50 day moving average of $38.79 and a 200 day moving average of $40.45. Sanofi has a 1-year low of $37.41 and a 1-year high of $51.88. The company has a market cap of $99.18 billion, a price-to-earnings ratio of 21.36 and a beta of 0.98.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/sanofis-sny-buy-rating-reaffirmed-at-leerink-swann-2.html
Several institutional investors have recently bought and sold shares of SNY. Bessemer Group Inc. raised its position in Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock valued at $144,000 after buying an additional 1,500 shares in the last quarter. Signaturefd LLC raised its position in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock valued at $146,000 after buying an additional 490 shares in the last quarter. JFS Wealth Advisors LLC raised its position in Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares in the last quarter. BlackRock Institutional Trust Company N.A. bought a new position in Sanofi during the first quarter valued at about $175,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in Sanofi during the second quarter valued at about $205,000. 9.42% of the stock is owned by hedge funds and other institutional investors.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.